Compare iShares MSCI Australia ETF (EWA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares MSCI Australia ETF trades at $28.52 (market cap $1.17B), while Recursion Pharmaceuticals Inc trades at $4.39 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap, and iShares MSCI Australia ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 63 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| EWA | RXRX | |
|---|---|---|
Market Cap | $1.17B | $2.14B |
Volume | 2,121,231 | 30,789,535 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $6.79 |
52-Week Low | $24.95 | $2.84 |
Typical Hold Time | 63 Days | 22 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Australia ETF (EWA) trades at $28.465, up 0.83% today, but technical indicators signal a bearish trend with all moving averages in sell territory. The ETF, which tracks Australian equities, faces headwinds from domestic market volatility and inflation concerns, as Australian shares recently hit a three-month low. Key support and resistance cluster tightly around $28, indicating a critical price zone. Financial ratios are unavailable in the provided data, limiting fundamental assessment.
Outlook remains cautious due to technical weakness and macroeconomic pressures, though some analysts see upside potential from commodity exposure. Risks include persistent inflation, tight monetary policy, and global economic shifts. Investors should weigh the bearish technicals against Australia's resource-driven economic prospects.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
